- Conditions
- Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- 18F-DCFPyL, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Carcinoma Non-resectable, Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine, nab-Paclitaxel
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, ABVD regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 37
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 29 more
- Conditions
- Shingles, Herpes Zoster
- Interventions
- Zostavax, HZ/su vaccine, Placebo
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hepatitis C
- Interventions
- Infliximab, Placebo
- Drug
- Lead sponsor
- Nizar Zein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Port Orange, Florida • Louisville, Kentucky + 3 more
- Conditions
- Hormone-sensitive Metastatic Breast Cancer
- Interventions
- OSI-906, Erlotinib, Letrozole, Goserelin
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Franklin, Tennessee • Nashville, Tennessee
- Conditions
- Rabies Human
- Interventions
- Rabies Vaccine, Metronidazole, Vancomycin, Neomycin Sulfate
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
- Interventions
- Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Coronary Syndrome
- Interventions
- Regular Insulin
- Drug
- Lead sponsor
- Universidade Positivo
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- enzastaurin, pemetrexed, docetaxel, carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Cyclophosphamide/Glatiramer acetate
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 29
- States / cities
- Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
- Drug · Radiation · Device
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- IMC-A12, cetuximab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Buffalo, New York + 1 more
- Conditions
- Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
- Interventions
- BLU-701, osimertinib, carboplatin, pemetrexed
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, cetuximab, FOLFIRI regimen, FOLFOX regimen, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C, oxaliplatin, therapeutic conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Winston-Salem, North Carolina
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin detemir, Dietary regimen
- Drug · Dietary Supplement
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL)
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Diabetes
- Interventions
- Glargine insulin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Haemophilia A
- Interventions
- Recombinant Factor VIII (Kovaltry, BAY81-8973)
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 4
- States / cities
- New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Alemtuzumab plus Fludarabine
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Berkeley, California • Burbank, California + 24 more
- Conditions
- Healthy
- Interventions
- Saline, Glucagon, Placebo, Atenolol
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Pregnancy, Prolonged
- Interventions
- Propranolol Hydrochloride, Saline
- Drug · Other
- Lead sponsor
- Lisa Levine
- Other
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania